EU Preparing Guidance On Synthetic Oligonucleotides & Peptides
Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.
You may also be interested in...
Oligonucleotides, Oxycodone And Osteoarthritis Among 49 US FDA Guidances
The FDA has seemingly followed the lead of the EMA by guiding ANDA sponsors on how to develop oligonucleotide drugs, a complex class of DNA or RNA molecules.
Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.
Antisense Oligonucleotide Clinical Guidance Emphasizes Individualized Nature Of Treatment
US FDA’ s latest ‘n of 1’ guidance describes clinical considerations for INDs to support dosing and monitoring of an individual with a life-threatening genetic disease who is eligible to receive an ASO; recommendations apply only when a few patients may be candidates for treatment.